X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA GSK PHARMA SHASUN PHARMA/
GSK PHARMA
 
P/E (TTM) x 123.9 62.6 198.0% View Chart
P/BV x 8.5 12.6 67.7% View Chart
Dividend Yield % 0.2 2.3 10.2%  

Financials

 SHASUN PHARMA   GSK PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
GSK PHARMA
Mar-18
SHASUN PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs942,760 3.4%   
Low Rs462,040 2.2%   
Sales per share (Unadj.) Rs214.2339.0 63.2%  
Earnings per share (Unadj.) Rs5.341.4 12.9%  
Cash flow per share (Unadj.) Rs15.845.9 34.5%  
Dividends per share (Unadj.) Rs1.0035.00 2.9%  
Dividend yield (eoy) %1.41.5 98.1%  
Book value per share (Unadj.) Rs53.3242.9 22.0%  
Shares outstanding (eoy) m56.6284.70 66.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.37.1 4.6%   
Avg P/E ratio x13.157.9 22.6%  
P/CF ratio (eoy) x4.452.3 8.5%  
Price / Book Value ratio x1.39.9 13.3%  
Dividend payout %18.784.5 22.2%   
Avg Mkt Cap Rs m3,958203,280 1.9%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1645,234 41.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,12728,715 42.2%  
Other income Rs m229545 42.0%   
Total revenues Rs m12,35629,260 42.2%   
Gross profit Rs m1,0095,059 19.9%  
Depreciation Rs m594380 156.2%   
Interest Rs m4152 20,755.0%   
Profit before tax Rs m2305,222 4.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m-731,892 -3.8%   
Profit after tax Rs m3023,508 8.6%  
Gross profit margin %8.317.6 47.2%  
Effective tax rate %-31.736.2 -87.4%   
Net profit margin %2.512.2 20.4%  
BALANCE SHEET DATA
Current assets Rs m6,88421,815 31.6%   
Current liabilities Rs m8,45615,999 52.9%   
Net working cap to sales %-13.020.3 -64.0%  
Current ratio x0.81.4 59.7%  
Inventory Days Days6264 96.9%  
Debtors Days Days10819 575.6%  
Net fixed assets Rs m4,97012,475 39.8%   
Share capital Rs m113847 13.4%   
"Free" reserves Rs m2,87519,726 14.6%   
Net worth Rs m3,02020,573 14.7%   
Long term debt Rs m1,8176 30,290.0%   
Total assets Rs m13,34739,475 33.8%  
Interest coverage x1.62,612.0 0.1%   
Debt to equity ratio x0.60 206,332.3%  
Sales to assets ratio x0.90.7 124.9%   
Return on assets %5.48.9 60.4%  
Return on equity %10.017.1 58.7%  
Return on capital %13.326.2 50.8%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,843564 1,035.9%   
Fx outflow Rs m2,1737,429 29.3%   
Net fx Rs m3,669-6,865 -53.5%   
CASH FLOW
From Operations Rs m3984,728 8.4%  
From Investments Rs m-1,635-1,042 156.9%  
From Financial Activity Rs m1,309-3,066 -42.7%  
Net Cashflow Rs m71620 11.5%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 3.6 10.2 35.3%  
FIIs % 17.6 23.8 73.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 15.4 257.1%  
Shareholders   20,750 102,036 20.3%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   VENUS REMEDIES  MERCK LTD  NOVARTIS  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

GSK PHARMA Plunges by 6%; BSE HEALTHCARE Index Down 0.9% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

GSK PHARMA share price has plunged by 6% and its current market price is Rs 1,624. The BSE HEALTHCARE is down by 0.9%. The top gainers in the BSE HEALTHCARE Index are BLISS GVS PHARMA (up 1.7%) and BIOCON LTD (up 0.5%). The top losers is GSK PHARMA (down 6.2%)..

DCM SHRIRAM Plunges by 6%; BSE 500 Index Down 0.8% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

DCM SHRIRAM share price has plunged by 6% and its current market price is Rs 460. The BSE 500 is down by 0.8%. The top gainers in the BSE 500 Index are ASAHI INDIA (up 3.1%) and ENTERTAINMENT NETWORK (up 2.8%). The top losers are DCM SHRIRAM (down 5.6%) and GSK PHARMA (down 6.2%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - AUROBINDO PHARMA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS